Canada markets open in 8 hours 57 minutes

WPD Pharmaceuticals Inc. (WBIO.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.3500-0.0100 (-2.78%)
At close: 2:45PM EST
Sign in to post a message.
  • d
    daniel
    What happened Here? Anyone ? $10 to $1 in 1 day?
  • S
    Scott
    Is this stock supposed to start trading again tomorrow?
  • K
    Knox
    strong
  • H
    Hubert
    Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100%
    https://finance.yahoo.com/news/moleculin-announces-active-compound-wp1122-113000553.html
  • B
    Be|Gone2019
    Strong buy?
    What is the one year target price?
  • B
    BETBIG
    WPD Pharmaceuticals' Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity
    3:05 am ET April 23, 2020 (Globe Newswire) Print
    WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the "Company" or "WPD") a clinical stage pharmaceutical company is pleased to provide an update on its Annamycin drug candidate. Through its license partner, Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin"), an open label, single arm US Phase 1 trial has been completed on its Annamycin drug candidate. The phase 1 trial met its objective of demonstrating the safety of Annamycin. Annamycin is intended for use in treating relapsed or refractory acute myeloid leukemia ("AML"). WPD has licensed rights to a portfolio of drug candidates, including Annamycin, from Moleculin.

    The US Phase 1 trial shows the safety of Annamycin in a phase I trial setting when delivered to patients at or below the lifetime maximum anthracycline dose established by the FDA. The primary safety signal was the absence of cardiotoxicity (potential damage to the heart), a serious and often treatment-limiting issue prevalent with currently approved anthracyclines. This was determined by echocardiograms, as well as cardiac health biomarkers, principally blood troponin levels, which are considered an indicator of potential long-term heart damage. The data showed no cardiotoxicity in any of the 6 patients evaluated in the US Phase 1 trial. Additionally, there were no unexpected serious adverse events and no dose limiting toxicities at any dose tested.

    Although the primary objective of the Phase 1 trial was to evaluate safety, the study also gathered data to support a preliminary assessment of the product's potential efficacy. Among other things, the study recorded complete response (CR), partial response (PR), event-free survival, overall survival (Kaplan-Meier), and time to and duration of remission/response. Based on these criteria, possible efficacy was seen in 2 of the US patients, even though the drug was dosed at what was expected to be sub-therapeutic levels. The evidence of efficacy consisted of 1 patient who achieved a "morphologically leukemia-free state," which the protocol defined as a CR with incomplete recovery of platelets or neutrophils (CRi), and another patient who had a substantial remission of leukemia cutis (a somewhat rare leukemia symptom), from diffuse to 3 small lesions.

    Mariusz Olejniczak, CEO of WPD commented, "We are encouraged by this kind of early activity during the Phase 1 trials of Annamycin, especially since these trials are typically designed to demonstrate safety, not efficacy, and the dosing was at levels we expected to be sub-therapeutic. Annamycin is being studied as a single agent, not in combination with any other drugs, and we believe this could be significant, because clinical advisors believe the vast majority of relapsed or refractory AML patients do not respond to single agents. FDA has already granted Fast Track designation, which recognizes that Annamycin shows the potential to address unmet medical needs, which can include providing efficacy comparable to available therapies while avoiding toxicity associated with the existing treatment. We look forward to our continued work with Moleculin on the advances of our drug candidate, Annamycin and the potential validation of these results in further study."
  • a
    ashish
    Loaded on this dip see yaa soon at 100% up 🏋🏿🙏🏿
  • f
    fillin
    These pharmas are in a great environment, if you're looking for the next great play in the Canadian markets check out SmallCapCanada, they are always focused on the undervalued and overlooked companies that are showing strong signs of growth and they deliver quality reports that are packed with insightful info- SmallCapCanada
  • L
    Loading
    Trend is moving up up
  • D
    Daniel
    Got news going today
  • D
    Daniel
    Strange .... some guy from an investor company calling me every day to buy .... says going to $ 2.00 to $ 2.50 in the next 2 weeks based on analysts estimates and news coming. Wondering if anyone else getting these calls, or just a scam ?
  • O
    Omar
    insider info cure on the way fda filing soon.. buy now next mrna right here
  • B
    BETBIG
    WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin
    3:05 am ET April 24, 2020 (Globe Newswire) Print
    WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical stage pharmaceutical company is pleased to announced that its license partner, CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS") filed an application with the U.S. Food and Drug Administration ("FDA") under the Orphan Drug Act to receive Orphan Drug Designation ("ODD") for its brain cancer drug candidate, Berubicin. WPD was previously awarded a reimbursement grant of approximately $6 million by the Polish National Center for Research and Development for a Phase 2 study of Berubicin, in Poland.

    Under a prior developer, Berubicin, then known as RTA 744, was granted ODD by the FDA for the treatment of malignant gliomas. In the prior developer's Phase 1 trial of Berubicin, 44% of the patients received a significant clinical benefit from their treatment. Additionally, one patient in this study experienced a complete response to his treatment with Berubicin and remains alive today, 14 years after treatment.

    Mariusz Olejniczak, CEO of WPD commented, "In collaboration with our License partner, CNS, we are excited to announce this FDA submission for Berubicin, as it would if granted, award special status and accelerate the development of the drug candidate to treat glioblastoma, one of the world's most aggressive forms of cancer. We look forward to providing additional information on the initiation of a Phase II trial utilizing the $6 million grant to evaluate the effect of Berubicin on patients with glioblastoma later this year."
  • E
    Excited Pedestrian
    To develop in collaboration with CNS Pharmaceuticals antiviral drug candidates licensed from Moleculin Biotech for the international markets
    To develop in collaboration with CNS Pharmaceuticals antiviral drug candidates licensed from Moleculin Biotech for the international markets
    www.globenewswire.com
  • T
    Thomas
    what do you think about the news today. do you think it will raise up tomorrow?
  • t
    tobias
    nice
  • J
    JANE
    Hope u are in!

    Jane
  • S
    Scott
    Is this still halted?